Skip to main content
. 2019 Dec 5;2019(12):CD011260. doi: 10.1002/14651858.CD011260.pub2

Alexander 2004.

Methods Study design: interrupted time series, uncontrolled before‐and‐after. National surveillance data from 1990 to 2003 for cases of confirmed paralytic poliomyelitis. The Centers for Disease Control and Prevention (CDC) has maintained national poliomyelitis surveillance since 1955. This system relies on voluntary reporting of suspected cases from healthcare providers and laboratories through local and state health departments to the CDC, the Vaccine Adverse Events Reporting System, and the National Vaccine Injury Compensation Program. Although laboratory technology evolved during the study period, polioviruses were isolated and identified using conventional procedures of inoculation of processed specimens onto susceptible cell cultures. Isolates were then determined to be vaccine‐related by 1 of several standard molecular methods
Setting: USA
Study dates: 1990 to 2003
Participants Age: range = 19 to 35 months
Interventions To reduce the VAPP burden, national vaccination policy changed in 1997 from reliance on OPV to options for a sequential schedule of inactivated poliovirus vaccine (IPV) followed by OPV. In 2000, an exclusive IPV schedule was adopted.
Before: exclusive use of OPV scheme OOOO (OPV at 2, 4, 12 to 18 months and again at 4 to 6 years) between 1990 and 1996
After: sequential scheme IIOO (IPV at 2 and 4 months of age followed by OP\/ at 12 to 18 months and again at 4 to 6 years) between 1997 and 1999. 13 cases of VAPP occurred, none of them in persons who had followed the sequential IPV‐OPV or all‐IPV schedules.
Outcomes
  • Number of confirmed paralytic poliomyelitis cases*

  • Number of VAPP cases*

  • Ratio of VAPP cases per number of doses of OPV distributed* that occurred before, during, and after implementation of policy changes.


*The sources were national information systems.
Timing of outcome assessment: before, during, and after implementation of policy changes
Follow‐up: 3 years
Notes The last case of poliomyelitis in the USA due to indigenously acquired wild poliovirus occurred in 1979; however, as a consequence of oral poliovirus vaccine (OPV) use that began in 1961, an average of 9 cases of vaccine‐associated paralytic poliomyelitis (VAPP) were confirmed each year between 1961 and 1989.
Risk of bias
Bias Authors' judgement Support for judgement
ITS: protection against secular changes Low risk Comment: the intervention appears to occur independently of other changes over time for VAPP cases.
ITS: data were analysed appropriately Unclear risk Comment: data were presented but not analysed as ITS, therefore, we re‐analysed the data.
ITS: reason given for the number of points pre‐ and post‐intervention Low risk Comment: the rationale for the yearly points is justified in the context of national poliomyelitis surveillance.
ITS: shape of the intervention effect was specified Low risk Comment: data were analysed as an ITS but were re‐analysed as time series regression models were used to analyse the data
ITS/UBA: blinded assessment of primary outcome(s) Low risk Comment: outcome variable is objective (case of paralytic poliomyelitis).
ITS/UBA: reliable primary outcome measure(s) Low risk Comment: Centers for Disease Control and Prevention has maintained national poliomyelitis surveillance since 1955.
ITS: intervention unlikely to affect data collection Low risk Comment: sources and methods of data collection were the same before and after the intervention. The outcome variable is objective (case of paralytic poliomyelitis).
ITS: completeness of data set Low risk Comment: data set probably covers 80% to 100% of total number of episodes in study
UBA: follow‐up of professionals Low risk Comment: low risk of bias in the context of a proper national poliomyelitis surveillance
UBA: follow‐up of patients Low risk Comment: low risk of bias in the context of a proper national poliomyelitis surveillance
Conflict of interest Low risk Comment: not clearly stated. Probably internal support from study authors' affiliation institution: National Immunization Program and National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia